SCHEMBL28636689

SCHEMBL28636689

OCc1ccc(OCCCN2CCOCC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 10/20 0.73
▸ MAPK1 P28482 2/20 0.70
▸ ALDH1A1 P00352 1/20 0.70
▸ CYP1A2 P05177 1/20 0.70
▸ CHRM2 P08172 1/20 0.70
▸ CHRM1 P11229 1/20 0.70
▸ HTR2A P28223 1/20 0.70
▸ SCN1A P35498 1/20 0.70
▸ HTR2B P41595 1/20 0.70
▸ KCNH2 Q12809 1/20 0.70
▸ SCN2A Q99250 1/20 0.70
▸ SIGMAR1 Q99720 1/20 0.70
▸ SCN3A Q9NY46 1/20 0.70
▸ USP2 O75604 1/20 0.68
▸ LMNA P02545 1/20 0.68
▸ HRH2 P25021 1/20 0.60
▸ HRH1 P35367 1/20 0.60
▸ LTA4H P09960 1/20 0.59
▸ EPHX2 P34913 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2249548 0.92 LTA4H (0.69) HRH3MAPK1ALDH1A1CYP1A2CHRM2
Pramoxine SCHEMBL2505808 0.88 ALDH1A1 (0.75) HRH3MAPK1ALDH1A1CYP1A2CHRM2
Pramoxine SCHEMBL9719985 0.87 LMNA (0.76) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL8795711 0.85 HRH3 (0.70) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL13186317 0.85 HRH3 (0.80) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL4089206 0.84 HRH3 (1.00) HRH3
SCHEMBL17443428 0.84 HRH3 (0.74) HRH3MAPK1ALDH1A1CYP1A2CHRM2
Pramoxine SCHEMBL26020 0.83 ALDH1A1 (1.00) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL23963137 0.82 HRH3 (0.67) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL14058943 0.82 HRH3 (0.67) HRH3MAPK1ALDH1A1CYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 — — US disclosed
US-20220119394-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEONE MEDICINES I GMBH (CH) 2022-04-21 — — US disclosed
CN-113454086-A Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2021-09-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119394-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST TLR7, TLR1, TLR3 HRH3 324/4885MAPK1 672/4885ALDH1A1 1611/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 HRH3 324/4885MAPK1 672/4885ALDH1A1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback